Clinical and cost outcomes from different hyaluronic acid treatments in patients with knee osteoarthritis: evidence from a US health plan claims database. A Retrospective analyses

Clinical and cost outcomes from different hyaluronic acid treatments in patients with knee osteoarthritis: evidence from a US health plan claims database

Article specifications

This study was published in 2006 in journal of DRUGS IN CONTEXT (IF 2016: 1.30) by American Academy of Orthopedic Surgeons. This study is an analyses using IMS Health’s PharMetrics Plus Health Plan Claims Database were conducted by identifying knee OA patients with claims indicating initiation of HA treatment at an ‘index date’ during the selection period (2007–2010). Patients were required to be continuously enrolled in the database for 12 months preindex to 36 months postindex. A generalized linear model (GLM) with a gamma distribution and log-link function was used to model aggregate patient-based changes in disease-specific costs.

Results

The results of the study showed that some intra-articular HA products may offer more value in delaying TKR than other HA products. The current finding also suggests that explanation of real-world clinical outcomes for IAHA may require considerations that go beyond simple categorization of HA by molecular weight or production process.